Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

Pamela Esposito Biography and Net Worth

Insider of Replimune Group

Pamela Esposito has served as Chief Business Officer since the inception of Replimune. Pamela has held a variety of strategy, commercial and business development positions in small biotech companies over the past 15 years, playing lead roles in transformative deals for each company. Previously, she was Chief Business Officer at Ra Pharmaceuticals. As a member of Ra’s senior management team, Pamela played a leadership role in strategy, helping Ra transform from a discovery platform to a clinical stage company and raising approximately $58 million in a Series B mezzanine funding round. Prior to Ra, she was VP of Business Development at Biovex and led the negotiation of the acquisition of the company by Amgen. Early in her career, she was a director at Bioduro based in Beijing, China and Vion Pharmaceuticals in New Haven, CT. Currently, Pamela sits on the board of directors of Accent Therapeutics. Pamela earned a Ph.D. in pharmacology from Tufts University School of Medicine and a B.A. from Dartmouth College.

What is Pamela Esposito's net worth?: The estimated net worth of Pamela Esposito is at least $1.70 million as of September 11th, 2023. Dr. Esposito owns 263,436 shares of Replimune Group stock worth more than $1,699,162 as of April 20th. This net worth estimate does not reflect any other investments that Dr. Esposito may own. Additionally, Dr. Esposito receives an annual salary of $464,630.00 as Insider at Replimune Group. Learn More about Pamela Esposito's net worth.
How old is Pamela Esposito?: Dr. Esposito is currently 50 years old. There are 9 older executives and no younger executives at Replimune Group. The oldest executive at Replimune Group is Dr. Colin A. Love Ph.D., Chief Operating Officer, who is 66 years old. Learn More on Pamela Esposito's age.
What is Pamela Esposito's salary?: As the Insider of Replimune Group, Inc., Dr. Esposito earns $464,630.00 per year. There are 3 executives that earn more than Dr. Esposito. The highest earning executive at Replimune Group is Mr. Philip Astley-Sparke F.S.A., CEO & Director, who commands a salary of $1,070,000.00 per year. Learn More on Pamela Esposito's salary.
How do I contact Pamela Esposito?: The corporate mailing address for Dr. Esposito and other Replimune Group executives is 500 Unicorn Park, WOBURN MA, 01801. Replimune Group can also be reached via phone at (781) 222-9600 and via email at [email protected]. Learn More on Pamela Esposito's contact information.
Has Pamela Esposito been buying or selling shares of Replimune Group?: Pamela Esposito has not been actively trading shares of Replimune Group during the last quarter. Most recently, Pamela Esposito sold 5,358 shares of the business's stock in a transaction on Monday, September 11th. The shares were sold at an average price of $20.01, for a transaction totalling $107,213.58. Following the completion of the sale, the insider now directly owns 263,436 shares of the company's stock, valued at $5,271,354.36. Learn More on Pamela Esposito's trading history.
Who are Replimune Group's active insiders?: Replimune Group's insider roster includes Robert Coffin (Insider), Pamela Esposito (Insider), and Colin Love (COO). Learn More on Replimune Group's active insiders.
Are insiders buying or selling shares of Replimune Group?: During the last year, insiders at the sold shares 10 times. They sold a total of 121,134 shares worth more than $2,331,903.29. The most recent insider tranaction occured on November, 16th when insider Konstantinos Xynos sold 7,313 shares worth more than $79,857.96. Insiders at Replimune Group own 20.6% of the company. Learn More about insider trades at Replimune Group.
Information on this page was last updated on 11/16/2023.

Pamela Esposito Insider Trading History at Replimune Group

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/11/2023	Sell	5,358	$20.01	$107,213.58	263,436
8/22/2023	Sell	18,600	$20.01	$372,186.00	263,436
8/11/2023	Sell	1,400	$20.00	$28,000.00	263,436
7/10/2023	Sell	20,000	$21.58	$431,600.00	263,436
12/9/2022	Sell	15,000	$25.03	$375,450.00	229,402
5/16/2022	Sell	3,507	$14.59	$51,167.13	229,402
8/5/2021	Sell	25,800	$35.09	$905,322.00	214,359
7/21/2021	Sell	12,538	$33.17	$415,885.46	215,021
7/15/2021	Sell	4,600	$33.37	$153,502.00
1/19/2021	Sell	5,727	$42.47	$243,225.69	195,994
1/15/2021	Sell	29,273	$43.58	$1,275,717.34	195,994
10/14/2020	Sell	16,000	$32.90	$526,400.00	128,700
8/31/2020	Sell	5,000	$27.05	$135,250.00	117,700

Pamela Esposito Buying and Selling Activity at Replimune Group

Replimune Group Company Overview

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Today's Range

Now: $6.45

$6.33

$7.07

50 Day Range

MA: $7.97

$6.87

$9.03

2 Week Range

Now: $6.45

$5.89

$24.81

Volume

866,616 shs

Average Volume

829,538 shs

Market Capitalization

$395.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.21

Secret Bull Market Starts in This Unusual Sector

From Altimetry | Ad

Click for my No. 1 investment, all free of charge, click here.

Pamela Esposito Biography and Net Worth

What is Pamela Esposito's net worth?

How old is Pamela Esposito?

What is Pamela Esposito's salary?

How do I contact Pamela Esposito?

Has Pamela Esposito been buying or selling shares of Replimune Group?

Who are Replimune Group's active insiders?

Are insiders buying or selling shares of Replimune Group?